-+ 0.00%
-+ 0.00%
-+ 0.00%
Jinling Pharmaceutical (000919.SZ): Application for marketing licensing of ferrous succinate powder was accepted
Share
Listen to the news

Zhitong Finance App News, Jinling Pharmaceutical (000919.SZ) issued an announcement. The company's branch, Jinling Pharmaceutical Co., Ltd., Nanjing Jinling Pharmaceutical Factory recently received the “Notice of Acceptance” issued by the State Drug Administration (“State Drug Administration”). The company's application for a drug registration and marketing license for ferrous succinate powder was accepted by the State Drug Administration. The original research and license for ferrous succinate powder is French company Laboratoire X.O. It is mainly used for the prevention and treatment of iron deficiency anemia. As of the date of disclosure of the announcement, the original research drug for this product has not been marketed in China, and no generic drug has been approved in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending